D0304 US PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF LUKAS AMLER, ET AL

FOR: BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO EPIDERMAL GROWTH

FACTOR RECEPTOR MODULATORS

APPLICATION NO: 10/541,749

ART UNIT: 1643

CONFIRMATION NO: 9819

APPLICATION DATE: 01/08/2004 EXAMINER: GUSSOW, ANNE USPTO CUSTOMER NO: 23914

TRANSMITTED VIA EFS-WEB

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, Applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a PCT International Search Report. Copies of these references and the search report are enclosed herewith. Pursuant to the OG Notice of August 5, 2003 for U.S. national applications filed after June 30, 2003, the requirement for submitting a copy of each cited U.S. patent and each cited U.S. patent application publication is waived, copies of the U.S. patent and U.S. patent publications are not submitted.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Statement under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby state that each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Statement under 37 C.F.R. §1.704(d)

I, the undersigned attorney, hereby state that each item of information contained in this information disclosure statement was cited in any communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000

Paul D. Golian

Attorney for Applicants

Reg. No. 42,591

Phone: 609-252-4091

Date: 2/7/68